South-East Asia Rheumatoid Arthritis Therapeutics Market 2022 South-East Asia Rheumatoid Arthritis Therapeutics | Page 3

Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in
Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks
associated with product development?
Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to
increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East
Asia markets?
Rising RA prevalence population and the uptake of newer therapies will lead to significant market
growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of
existing drugs?
Downlo ad sample Copy of This Report at:
http://www.radiantinsights.com/research/rheumatoid-arthritis-therapeutics-in-south-
east-asia-markets-to-2022/request-sample
Reasons to buy
This report will enable you to -
- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and
pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed
products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target,
and novelty.
- Consider market opportunities and potential risks by examining trends in RA clinical trial size,
duration, and failure rate by stage of development, molecule type, and molecular target.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential
in RA by examining clinical trial data and multi-scenario product forecast projections.
Follow Us: